Physician profile
Tandy Smith
NPI 1457632721
$3,128.41
in general payments reported to CMS, 2019-2025
30 companies · $54.17 in 2025
The $54.17 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $720 · 2022: $650 · 2023: $829 · 2024: $875 · 2025: $54.17.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,758.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $465.93 | 2021-2024 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals Lp | $409.16 | 2021-2024 | Airsupra, Breztri, Farxiga |
| Abbvie INC. | $327.83 | 2021-2024 | |
| Lilly USA, LLC | $321.67 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $285.94 | 2021-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $209.09 | 2021-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $162.18 | 2022-2024 | Rexulti |
| Pfizer INC. | $126.50 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $125.65 | 2021-2022 | |
| Boston Scientific Corporation | $96.98 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $87.04 | 2021-2023 | |
| Corcept Therapeutics | $78.23 | 2023 | Korlym |
| Idorsia Pharmaceuticals US INC | $63.45 | 2022-2024 | Quviviq |
| Exact Sciences Corporation | $48.39 | 2023-2024 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $39.77 | 2022-2023 | Livalo, Seglentis |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $27.08 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $25.33 | 2022-2023 | Eliquis |
| Lundbeck LLC | $24.43 | 2024 | Rexulti |
| Biohaven Pharmaceutical Holding Company Ltd. | $23.30 | 2022 | |
| Janssen Pharmaceuticals, INC | $21.73 | 2022 | |
| Pulmonx Corporation | $19.80 | 2025 | Chartis Catheter, Zephyr Endobronchial Valve, Pulmonx Chartis Tablet Console |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.88 | 2023 | Jardiance |
| Dexcom, INC. | $17.73 | 2024 | Dexcom G6 Transmitter |
| Supernus Pharmaceuticals, INC. | $17.55 | 2021 | |
| Axsome Therapeutics, INC. | $16.84 | 2023 | Auvelity |
| Genentech USA, INC. | $13.77 | 2021 | |
| Vanda Pharmaceuticals INC. | $13.70 | 2024 | Fanapt |
| Xeris Pharmaceuticals, INC. | $13.68 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.56 | 2021 | |
| Phathom Pharmaceuticals, INC. | $13.22 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tandy Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.